NEW YORK, Dec. 13 - Paradigm Therapeutics, of Cambridge, UK, has signed a three-year collaboration with Swedish biopharma Medavir, to discover new protease drug targets, the company said Friday.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Japan Times says regulations are needed to oversee human genome-editing research.
In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.
At Wired, a science journalist discusses her decision not to undergo BRCA testing.
In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.